CCL2 and triple-A syndrome: Our results showed that formoterol dose independently inhibited expression of IL‐6, MCP1, and VCAM in EPO‐induced AAA, which is consistent with the anti‐inflammatory effects of formoterol in respiratory diseases, suggesting that anti‐inflammation may be the key mechanism of formoterol treatment in EPO‐induced AAA.